Cephalon is requesting expanded FDA approval for the use of its "breakthrough pain" cancer drug Fentora in opioid-tolerant patients suffering from chronic pain. The company and the FDA previously issued warnings about the potential fatal risk linked to the misuse of Fentora, but the company said at that time it was working with the agency on revised patient selection criteria and dosing instructions for the drug's packaging.

Related Summaries